Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 355

1.

Medicinal Cannabis in Pregnancy - Panacea or Noxious Weed?

O'Connor M.

J Law Med. 2018 Apr;25(3):634-646.

PMID:
29978658
2.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

3.

Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases.

Prandi C, Blangetti M, Namdar D, Koltai H.

Molecules. 2018 Jun 25;23(7). pii: E1526. doi: 10.3390/molecules23071526. Review.

4.

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.

Mouhamed Y, Vishnyakov A, Qorri B, Sambi M, Frank SS, Nowierski C, Lamba A, Bhatti U, Szewczuk MR.

Drug Healthc Patient Saf. 2018 Jun 11;10:45-66. doi: 10.2147/DHPS.S158592. eCollection 2018. Review.

5.

Cannabinoids for Treatment of MS Symptoms: State of the Evidence.

Rice J, Cameron M.

Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Review.

PMID:
29923025
6.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

7.

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

Celius EG, Vila C.

Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May.

8.

Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.

Abdollahpour I, Nedjat S, Mansournia MA, Schuster T.

PLoS One. 2018 Apr 24;13(4):e0196244. doi: 10.1371/journal.pone.0196244. eCollection 2018.

9.

[Cannabinoid therapy in practice].

Rasche T, Emmert D, Stieber C, Mücke M, Conrad R.

Urologe A. 2018 May;57(5):558-562. doi: 10.1007/s00120-018-0636-0. Review. German.

PMID:
29651709
10.

Cannabidiol to Improve Mobility in People with Multiple Sclerosis.

Rudroff T, Sosnoff J.

Front Neurol. 2018 Mar 22;9:183. doi: 10.3389/fneur.2018.00183. eCollection 2018. No abstract available.

11.

Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice.

Landa L, Jurica J, Sliva J, Pechackova M, Demlova R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Mar;162(1):18-25. doi: 10.5507/bp.2018.007. Epub 2018 Mar 19.

12.

Optimization of Δ9-tetrahydrocannabinolic acid synthase production in Komagataella phaffii via post-translational bottleneck identification.

Zirpel B, Degenhardt F, Zammarelli C, Wibberg D, Kalinowski J, Stehle F, Kayser O.

J Biotechnol. 2018 Apr 20;272-273:40-47. doi: 10.1016/j.jbiotec.2018.03.008. Epub 2018 Mar 13.

PMID:
29549004
13.

Evaluation of Marijuana Compounds on Neuroimmune Endpoints in Experimental Autoimmune Encephalomyelitis.

Kaplan BLF.

Curr Protoc Toxicol. 2018 Feb 21;75:11.25.1-11.25.22. doi: 10.1002/cptx.43.

PMID:
29512125
14.

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.

Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M.

Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8. doi: 10.1007/s11910-018-0814-x. Review.

PMID:
29442178
15.

Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.

Tomas-Roig J, Piscitelli F, Gil V, Quintana E, Ramió-Torrentà LL, Del Río JA, Moore TP, Agbemenyah H, Salinas G, Pommerenke C, Lorenzen S, Beißbarth T, Hoyer-Fender S, Di Marzo V, Havemann-Reinecke U.

CNS Neurosci Ther. 2018 Jun;24(6):528-538. doi: 10.1111/cns.12810. Epub 2018 Jan 31.

16.

The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report.

Abrams DI.

Eur J Intern Med. 2018 Mar;49:7-11. doi: 10.1016/j.ejim.2018.01.003. Epub 2018 Jan 9. Review.

PMID:
29325791
17.

Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview.

Capasso A.

Open Neurol J. 2017 Dec 18;11:61-73. doi: 10.2174/1874205X01711010061. eCollection 2017. Review.

18.

Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.

Brenton JN, Schreiner T, Karoscik K, Richter M, Ferrante S, Waldman A, Banwell B.

J Neurol. 2018 Feb;265(2):417-423. doi: 10.1007/s00415-017-8715-5. Epub 2017 Dec 22.

PMID:
29273844
19.

Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Oláh A, Szekanecz Z, Bíró T.

Front Immunol. 2017 Nov 10;8:1487. doi: 10.3389/fimmu.2017.01487. eCollection 2017. Review.

20.

The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.

Russo M, Dattola V, Logiudice AL, Ciurleo R, Sessa E, De Luca R, Bramanti P, Bramanti A, Naro A, Calabrò RS.

Medicine (Baltimore). 2017 Nov;96(46):e8826. doi: 10.1097/MD.0000000000008826.

Supplemental Content

Loading ...
Support Center